Certara (NASDAQ:CERT) Releases FY 2024 Earnings Guidance

Certara (NASDAQ:CERT - Get Free Report) updated its FY 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.410-0.460 for the period, compared to the consensus EPS estimate of 0.430. The company issued revenue guidance of $385.0 million-$400.0 million, compared to the consensus revenue estimate of $388.5 million.

Wall Street Analysts Forecast Growth

CERT has been the topic of several recent analyst reports. JMP Securities began coverage on shares of Certara in a research report on Thursday, April 4th. They set a market perform rating on the stock. KeyCorp upgraded Certara from a sector weight rating to an overweight rating and set a $23.00 price objective for the company in a research report on Wednesday, April 10th. Leerink Partnrs reissued a market perform rating on shares of Certara in a research note on Monday, February 26th. UBS Group upped their price objective on Certara from $17.00 to $20.00 and gave the stock a neutral rating in a report on Friday, March 1st. Finally, SVB Leerink assumed coverage on shares of Certara in a report on Monday, February 26th. They issued a market perform rating and a $19.00 target price for the company. Seven research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of Hold and a consensus price target of $20.06.

Certara Trading Down 7.4 %

NASDAQ CERT traded down $1.31 on Wednesday, hitting $16.35. 957,638 shares of the stock were exchanged, compared to its average volume of 537,561. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.62 and a current ratio of 2.62. Certara has a 52-week low of $11.81 and a 52-week high of $22.65. The firm has a market capitalization of $2.62 billion, a P/E ratio of -47.71, a P/E/G ratio of 1.81 and a beta of 1.61. The stock has a fifty day moving average price of $17.72 and a two-hundred day moving average price of $16.44.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings data on Thursday, February 29th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.04). The business had revenue of $88.01 million for the quarter, compared to analysts' expectations of $86.80 million. Certara had a negative net margin of 15.62% and a positive return on equity of 4.33%. Research analysts forecast that Certara will post 0.29 EPS for the current fiscal year.

Insider Transactions at Certara

In related news, insider Patrick F. Smith sold 14,427 shares of the business's stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $16.85, for a total value of $243,094.95. Following the completion of the sale, the insider now owns 50,091 shares in the company, valued at $844,033.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Richard M. Traynor sold 3,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $18.00, for a total transaction of $54,000.00. Following the transaction, the senior vice president now directly owns 173,524 shares in the company, valued at $3,123,432. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Patrick F. Smith sold 14,427 shares of the business's stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $16.85, for a total transaction of $243,094.95. Following the completion of the transaction, the insider now directly owns 50,091 shares of the company's stock, valued at approximately $844,033.35. The disclosure for this sale can be found here. Over the last three months, insiders have sold 23,427 shares of company stock valued at $405,095. 2.39% of the stock is currently owned by company insiders.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.